

Supplementary material to article by L. Turner-Stokes et al. "Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study"

**Table SIII.** Changes in injection practice over the cycles

Parameter, n (%)	Change from Cycle 1 to Cycle 2 n = 840	Change from Cycle 2 to Cycle 3 n = 744	Change from Cycle 3 to Cycle 4 n = 593	Change from Cycle 4 to Cycle 5 n = 377	Change from Cycle 5 to Cycle 6 n = 213	Change from Cycle 6 to Cycle 7 n = 105
Patients with a change in injection practice vs prior injection	580 (69.1)	513 (69.0)	366 (61.7)	235 (62.3)	114 (53.5)	50 (47.6)
<i>Reason for change in injection practice</i>						
Due to a clinical reason	519 (89.6)	468 (91.2)	316 (86.3)	199 (84.7)	102 (89.5)	41 (82.0)
Lack of effect with previous injection plan	128 (24.7)	114 (24.4)	82 (25.9)	48 (24.1)	27 (26.5)	12 (29.3)
Change in intervention goal	282 (54.3)	225 (48.1)	145 (45.9)	80 (40.2)	26 (25.5)	14 (34.1)
New significant event	38 (7.3)	19 (4.1)	13 (4.1)	7 (3.5)	6 (5.9)	0
Good efficacy but change in injection pattern	71 (13.7)	110 (23.5)	76 (24.1)	64 (32.2)	43 (42.2)	15 (36.6)
Due to a non-clinical reason	5 (0.9)*	8 (1.6)	5 (1.4)	1 (0.4)	0	0
Cost issues (in case of out-of-pocket payment)	1 (25.0)	3 (37.5)	1 (20.0)	0		
Change of service provider	3 (75.0)	5 (62.5)	4 (80.0)	1 (100.0)		
Other reason	55 (9.5)	37 (7.2)	45 (12.3)	35 (14.9)	12 (10.5)	9 (18.0)
<i>Type of change</i>						
With change in BoNT-A product	61 (10.5)	62 (12.1)	47 (12.8)	24 (10.2)	11 (9.6)	5 (10.0)
With change in muscles or dose per muscle	519 (98.5)	451 (98.7)	319 (99.4)	211 (99.5)	103 (100.0)	45 (100.0)

\*One patient missing. BoNT-A: botulinum toxin A.